Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $114 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) with a maintained price target of $114.
January 19, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst reaffirms Overweight rating on Ultragenyx Pharmaceutical with a steady price target of $114, indicating a positive outlook on the stock.
The reiteration of an Overweight rating by a reputable analyst, along with the maintenance of a high price target, suggests a strong vote of confidence in Ultragenyx Pharmaceutical's stock. This could lead to increased investor interest and potentially a positive short term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100